stonks4u
Sign up free
APVO logo

APVO Aptevo Therapeutics Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$2.94
-0.46 (-13.44%)

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyon…

Market Cap: $6.43Mwww.aptevotherapeutics.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

120
8093107120
Aug 12Aug 14

Quote

Day Range
$2.90 – $3.35
52-Week Range
$2.84 – $48.78
Volume
$79.0K
Market Cap
$6.43M
50-Day Avg
$4.38
200-Day Avg
$9.20
Prev Close
$3.40
Open
$3.31

Valuation & Ratios

P/E Ratio
-0.11
EPS
$-8230.43
P/B Ratio
0.00
P/S Ratio
0.00
Debt/Equity
0.27
Current Ratio
3.82
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-149.4%
Return on Assets
-95.5%
FCF Yield
-86018.8%
EV/EBITDA
0.66

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-25.97M$-87.27
2024$0.00$-24.13M$-31458.00
2023$0.00$-17.41M$-834044.00
2022$3.11M$8.03M$922390.00
2021$12.29M$-28.46M$-3557646.00

Social Signal Score

44
5d
45
3 mentions
—
30d
44
3 mentions
—
60d
44
3 mentions
—
90d
44
3 mentions
—
news: 3

Earnings

Thu, Nov 5(in 3 months)

Consensus estimate $-5.67 per share

2of 7 quarters beat consensus

Typical surprise -6.7% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 14$-5.31 vs $-6.01beat
  • Wed, May 13$-6.41 vs $-5.60miss
  • Fri, Mar 20$1684.47 vs $-8.09beat
  • Thu, Nov 6$-40.11 vs $-37.59miss
  • Mon, Aug 11$-151.08 vs $-0.45miss
  • Thu, May 15$-1579.14 vs $-1514.39miss

Estimates and results for APVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

APVOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (3)

  • Newsaccessnewswire.com·1d ago·Positive

    …tline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor Strategy Strategic Niowave Collaboration Opens a New Radiopharmaceutical Therapeutic Development Opportunity SEATTLE, WA / ACCESS Newswire / August 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics base…

    View source ↗
  • Newsaccessnewswire.com·1d ago·Negative

    …ces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously announced warrant inducement transaction with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have exercised in f…

    View source ↗
  • Newsaccessnewswire.com·3d ago·Negative

    Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds SEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced it has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holde

    View source ↗